John Jordan - Viridian Therapeutics Vice Communications
| VRDN Stock | USD 21.87 0.04 0.18% |
Executive
John Jordan is Vice Communications of Viridian Therapeutics
| Address | 221 Crescent Street, Waltham, MA, United States, 02453 |
| Phone | 617 272 4600 |
| Web | https://www.viridiantherapeutics.com |
Viridian Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3215) % which means that it has lost $0.3215 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5188) %, meaning that it created substantial loss on money invested by shareholders. Viridian Therapeutics' management efficiency ratios could be used to measure how well Viridian Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Tangible Assets is likely to drop to -0.51. In addition to that, Return On Capital Employed is likely to grow to -0.52. At this time, Viridian Therapeutics' Total Assets are very stable compared to the past year. As of the 28th of November 2024, Non Currrent Assets Other is likely to grow to about 1 M, while Non Current Assets Total are likely to drop about 2.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| MD MBA | Eliem Therapeutics | 50 | |
| Caroline MD | Ikena Oncology | 52 | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| Nicole Esq | HCW Biologics | N/A | |
| David Ege | Seres Therapeutics | 49 | |
| Valdas Jurkauskas | Ikena Oncology | N/A | |
| David MS | Ikena Oncology | N/A | |
| Lee Flowers | HCW Biologics | 78 | |
| John PharmD | Scpharmaceuticals | N/A | |
| Michael Hassman | Scpharmaceuticals | N/A | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| RPh Young | Seres Therapeutics | 57 | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| JD Esq | Seres Therapeutics | 69 | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| Eddie MBA | Lumos Pharma | N/A | |
| MD FAAP | Lumos Pharma | N/A | |
| Caroline Holda | Seres Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.32 |
Viridian Therapeutics Leadership Team
Elected by the shareholders, the Viridian Therapeutics' board of directors comprises two types of representatives: Viridian Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Viridian. The board's role is to monitor Viridian Therapeutics' management team and ensure that shareholders' interests are well served. Viridian Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Viridian Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Seth Harmon, Principal Accounting | ||
| Anthony Casicano, Chief Officer | ||
| Kristian MBA, Chief CFO | ||
| Melissa Manno, Chief Officer | ||
| Anthony Casciano, Chief Officer | ||
| MBA JD, President CEO | ||
| Jennifer JD, Chief Officer | ||
| Eric Olson, CoFounder Board | ||
| MBA MD, Chief Officer | ||
| MD MBA, Chief Officer | ||
| Jonathan MBA, CEO, CoFounder | ||
| Rob Henderson, Chief Officer | ||
| Carrie MBA, Chief Officer | ||
| John Jordan, Vice Communications | ||
| Marvin Caruthers, CoFounder Member | ||
| Shan Wu, Chief Officer | ||
| Vahe Bedian, CoFounder Scientist | ||
| Lara Meisner, Sr Counsel | ||
| CMO MBA, Chief Officer | ||
| Todd IRC, Sr Relations | ||
| Helen Milton, Senior Assurance |
Viridian Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Viridian Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.32 | ||||
| Operating Margin | (970.70) % | ||||
| Current Valuation | 1.19 B | ||||
| Shares Outstanding | 79.21 M | ||||
| Shares Owned By Institutions | 100.00 % | ||||
| Number Of Shares Shorted | 9.1 M | ||||
| Price To Book | 3.34 X | ||||
| Price To Sales | 5,736 X | ||||
| Revenue | 314 K |
Pair Trading with Viridian Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Viridian Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viridian Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Viridian Stock
Moving against Viridian Stock
| 0.66 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.63 | INKT | Mink Therapeutics | PairCorr |
| 0.52 | PIRS | Pieris Pharmaceuticals | PairCorr |
| 0.45 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
| 0.39 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
The ability to find closely correlated positions to Viridian Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Viridian Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Viridian Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Viridian Therapeutics to buy it.
The correlation of Viridian Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Viridian Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Viridian Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Viridian Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.32) | Revenue Per Share 0.005 | Quarterly Revenue Growth 0.194 | Return On Assets (0.32) | Return On Equity (0.52) |
The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.